A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
about
Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia.Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study.Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goalsPitavastatin: a new HMG-CoA reductase inhibitor.Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.Pitavastatin: evidence for its place in treatment of hypercholesterolemia.New lipid-modifying therapies.New drugs for the treatment of hypercholesterolaemia.Cholesterol management and the reduction of cardiovascular risk.Statins: can the new generation make an impression?Pitavastatin: efficacy and safety in intensive lipid lowering.Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin Under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study).Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells.New evidence on pitavastatin: efficacy and safety in clinical studies.Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis.Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.Statin use and the risk of developing diabetes: a network meta-analysis.Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes.Pitavastatin: A Review in Hypercholesterolemia.PROPIT: A PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome.Lipid peroxidation-induced VEGF expression in the skin of KKAy obese mice.Effects of Different Types of Statins on Lipid Profile: A Perspective on Asians.Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosisComparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.Detection of vascular disease risk in women by panoramic radiography.Interaction between fibrates and statins--metabolic interactions with gemfibrozil.Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia.Patterns and predictors of physician adoption of new cardiovascular drugs.Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase.
P2860
Q33902665-F40AD171-B9E2-49BA-A617-405FC07C9565Q34334852-6FDA3914-D36E-4A91-B4B7-7BB79700C153Q34451383-7747229F-4DCD-459A-A8D3-0ACDE5AAEC05Q34614726-50420CCC-BD42-4A34-93A5-99FDA404B1C9Q34617057-413755EB-5EB5-4462-88E1-8895B6D6748CQ34625887-66834D75-765A-4C61-852C-675419423535Q34628242-FA7387E7-2760-4568-918D-6E919B994C29Q35073322-A64D9BE4-9331-4E50-9ADC-CB0816F41EFCQ35570944-771A5242-7CBF-4B3B-9F37-8A5476FF779CQ35686489-78A1AC43-E6C4-4217-8D81-8C7A41FDC41DQ35967383-7C22EEE4-79CA-4946-BB3D-0A20155CE368Q36967274-47E060F6-8661-4098-9D5C-DDFFFC6B7B05Q36976354-869D6D6E-78AF-4C24-95BB-1AAE5E6D4714Q37165112-524EE785-1C6F-475A-97F8-402D19102B86Q37702244-076E2800-00F6-4B41-B815-7E4EE81E4160Q37776512-192B3BB7-7081-4C6C-B313-89C4DE192A71Q37859000-A3E59AEA-330B-4831-B520-2472A7198439Q37880123-68317DDD-C111-4725-AE94-8822380AA01EQ38161516-5AF3B90E-8569-4E33-9E60-07A1C62A38A4Q38859404-2D3AABC3-4881-4D14-994E-6B20D541436DQ38881481-2A144A9F-9157-489F-812F-DAC00A0405CEQ39107221-00343872-7FE7-4EA8-BF86-BB3A5A785054Q39146765-36FEE3C4-4462-4844-99B0-90F3716F593AQ39585247-05697037-8501-448C-BFBC-281ADEC316F2Q41391827-9FB8CEB0-4FD6-40B4-9D16-205E71BA7B4BQ41813708-0067C47C-F3B7-4C64-8E2B-CA4AC31F32BEQ43152513-12A0A014-73FA-49C7-BDE8-DB3250F06CB8Q44599952-44BBE74A-FAC1-460C-849D-45F909765D2AQ44698041-C36AF953-9C71-4B44-BFF7-1CEE75709316Q46410210-09745071-ED4E-4C68-83A4-EDACF58E29EBQ46590970-4E561834-6E93-47E6-9483-68B7BE0C7431Q46783215-E601E939-10C0-4B28-9088-C3F7E85590D7
P2860
A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
A randomized, double-blind tri ...... primary hypercholesterolemia.
@en
A randomized, double-blind tri ...... primary hypercholesterolemia.
@nl
type
label
A randomized, double-blind tri ...... primary hypercholesterolemia.
@en
A randomized, double-blind tri ...... primary hypercholesterolemia.
@nl
prefLabel
A randomized, double-blind tri ...... primary hypercholesterolemia.
@en
A randomized, double-blind tri ...... primary hypercholesterolemia.
@nl
P2093
P1433
P1476
A randomized, double-blind tri ...... primary hypercholesterolemia.
@en
P2093
Hiroshi Mabuchi
Hiroshige Itakura
Jun Sasaki
Motoo Tushima
Nobuhiro Yamada
Nobuya Ogawa
Noriaki Nakaya
Tamio Teramoto
Yasushi Saito
Yoshiya Hata
P304
P356
10.1016/S0021-9150(01)00712-2
P577
2002-06-01T00:00:00Z